Label Changes for:

Parnate (tranylcypromine sulfate) tablets

November 2009

Changes have been made to the CONTRAINDICATIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010 and November 2009

CONTRAINDICATIONS

In combination with sympathomimetics
  • Parnate should not be administered in combination with sympathomimetics, including amphetamines which may be found in many herbal preparations
  • Cerebral hemorrhage may also occur

CONTRAINDICATIONS

  • Parnate is contraindicated: In combination with selective norepinephrine reuptake inhibitors (SNRIs)
Hide
(web2)